TABLE 2

The results of the Safety47 Panel

The assays were performed at 10 µM in agonist and antagonist mode, and the data were normalized (and presented as a percentage of response) to the maximal and minimal response observed in the presence of control ligand and vehicle.

TargetModeResponseTargetModeResponseTargetModeResponseTargetModeResponse
%%%%
ADORA2AAgonist−19.4CNR1Agonist63HTR2BAgonist−40.8KvLQT1/minKOpener−1.2
Antagonist17.8Antagonist−3.9Antagonist7.2Blocker12.7
ADRA1AAgonist−3.9CNR2Agonist16.3OPRD1Agonist22.4nAChR9(a4/b2)Opener−9.1
Antagonist−8.1Antagonist−9.4Antagonist−9.2Blocker37.4
ADRA2AAgonist24.3DRD1Agonist−0.7OPRK1Agonist25.5NMDAR(1A/2B)Opener−12.4
Antagonist−7.1Antagonist39.2Antagonist−1.1Blocker−16.4
ADRB1Agonist−0.1DRD2SAgonist17.2OPRM1Agonist20AChEInhibitor−2.8
Antagonist32.3Antagonist−0.9Antagonist−7.6hERGBlocker4.6
ADRB2Agonist−1EDNRAAgonist−3.9ARAgonist−0.6NAV1.5Blocker−7.2
Antagonist45.5Antagonist−8.3Antagonist7.1CoX1Inhibitor31
AVPR1AAgonist−3HRH1Agonist0.5GRAgonist1.8COX2Inhibitor−9.9
Antagonist−17.7Antagonist−8.9Antagonist−16.7MAOAInhibitor1.2
CCKARAgonist−1.9HRH2Agonist−1.2GABAAOpener−15.1PDE3AInhibitor−0.1
Antagonist−3Antagonist34.2Blocker6.4PDE4D2Inhibitor0.7
CHRM1Agonist−8.5HTR1AAgonist22.1HTR3AOpener−8.1INSRInhibitor−20
Antagonist−1Antagonist−17.9Blocker18.3LCKInhibitor10.5
CHRM2Agonist32.1HTR1BAgonist15.1DATBlocker11.1ROCK1Inhibitor−5
Antagonist−6.3Antagonist−5.2NETBlocker12.5VEGFR2Inhibitor−15
CHRM3Agonist−5HTR2AAgonist−5.4SERTBlocker12.6
Antagonist−3.2Antagonist6.3CAV1.2Blocker−21.1